Abstract
The genetic diagnosis of individuals at risk for hereditary cancer predisposition syndromes is performed through next-generation sequencing (NGS) of panels containing ten to hundreds cancer predisposition genes (CPGs). A significant part of genetic tests present uncertain results, with the identification of variants of unknown clinical significance (VUS), a finding that represents a major…